ALX Oncology Holdings Inc Sustainability Reports
ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company focused on developing therapies for cancer patients. Its lead product candidate is evorpacept, a CD47-blocking therapeutic biologic designed to combine with other anti-cancer agents.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
FIGI: BBG00VR8SF73
1 reports from 2024 to 2024
Company Profile
ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company focused on developing therapies for cancer patients. Its lead product candidate is evorpacept, a CD47-blocking therapeutic biologic designed to combine with other anti-cancer agents.
Reports
1 total
Limited sustainability disclosure available
This company only publishes Annual Reports without dedicated sustainability sections.
Years
